about
Anti-leishmanial activity of betulin derivatives.The role of the mitochondrial glycine cleavage complex in the metabolism and virulence of the protozoan parasite Leishmania majorUpdate in the treatment of cutaneous leishmaniasis.New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in childrenThe relationship between leishmaniasis and AIDS: the second 10 yearsLimited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.Seco-limonoid derived from Raputia heptaphylla promotes the control of cutaneous leishmaniasis in hamsters (Mesocricetus auratus).Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity.An orally effective dihydropyrimidone (DHPM) analogue induces apoptosis-like cell death in clinical isolates of Leishmania donovani overexpressing pteridine reductase 1.Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.Synergistic combination of alkylphosphocholines with peptaibols in targeting Leishmania infantum in vitro.Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.
P2860
Q33530052-1256A5A5-3A22-4264-8D06-09153425C8AAQ34235658-1522D2F4-3F84-46B7-A6D3-B60E65D2A20CQ34421618-A309C6FC-D49A-497D-91C4-FF7D435D5E2DQ35219247-DB44B10C-D563-48D1-BF47-878B5D6DB373Q35694752-45AA95F0-52C8-4173-AFED-04EA06FA752FQ36538814-5EC64EC9-81AA-4467-A7EE-2AC9A9032BF7Q36558539-84D4E91C-0591-4BC7-8DB6-BC43664132DDQ36803937-5AD3F6F6-4FF4-4A53-A4AE-EAB3941D8364Q37615730-12EEFAA5-EB7A-4B11-8874-FAF2730CD6F9Q40861083-805D61C5-07EF-48C2-B0F7-A071DBD4E779Q41824183-D2F154D1-9129-4164-B3BC-33EABDDF6B51Q41844460-C3CC0989-37E3-4839-BE01-FA33ADE93490Q45185252-3CCE4568-D9B5-4FCF-A62F-38582A4F5323Q52598514-DAD9CB75-8142-41B7-A2A9-BB539DEE1456Q54961274-B8C02943-0AEE-4F8A-96CB-985867B04BC1
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Miltefosine: issues to be addressed in the future.
@ast
Miltefosine: issues to be addressed in the future.
@en
type
label
Miltefosine: issues to be addressed in the future.
@ast
Miltefosine: issues to be addressed in the future.
@en
prefLabel
Miltefosine: issues to be addressed in the future.
@ast
Miltefosine: issues to be addressed in the future.
@en
P2093
P1476
Miltefosine: issues to be addressed in the future
@en
P2093
Bryceson AD
Gutteridge W
Karbwang J
Sindermann H
P356
10.1016/J.TRSTMH.2006.02.009
P478
100 Suppl 1
P50
P577
2006-06-05T00:00:00Z